It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
During intercellular communication, cells release extracellular vesicles such as exosomes, which contain proteins, ncRNAs and mRNAs that can influence proliferation and/or trigger apoptosis in recipient cells, and have been proposed to play an essential role in promoting invasion of tumor cells and in the preparation of metastatic niches. Our group proposed the antisense non-coding mitochondrial RNA (ASncmtRNA) as a new target for cancer therapy. ASncmtRNA knockdown using an antisense oligonucleotide (ASO-1537S) causes massive death of tumor cells but not normal cells and strongly reduces metastasis in mice. In this work, we report that exosomes derived from ASO-1537S-treated MDA-MB-231 breast cancer cells (Exo-1537S) inhibits tumorigenesis of recipient cells, in contrast to exosomes derived from control-ASO-treated cells (Exo-C) which, in contrast, enhance these properties. Furthermore, an in vivo murine peritoneal carcinomatosis model showed that Exo-1537S injection reduced tumorigenicity compared to controls. Proteomic analysis revealed the presence of Lactadherin and VE-Cadherin in exosomes derived from untreated cells (Exo-WT) and Exo-C but not in Exo-1537S, and the latter displayed enrichment of proteasomal subunits. These results suggest a role for these proteins in modulation of tumorigenic properties of exosome-recipient cells. Our results shed light on the mechanisms through which ASncmtRNA knockdown affects the preparation of breast cancer metastatic niches in a peritoneal carcinomatosis model.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details



1 Clínica Alemana-Universidad del Desarrollo, Centro de Medicina Regenerativa, Facultad de Medicina, Santiago, Chile (GRID:grid.412187.9) (ISNI:0000 0000 9631 4901); Andes Biotechnologies/Fundación Ciencia & Vida, Santiago, Chile (GRID:grid.412187.9); Centro de Estudios Avanzados de Enfermedades Crónicas (ACCDIS), Santiago, Chile (GRID:grid.412187.9)
2 Andes Biotechnologies/Fundación Ciencia & Vida, Santiago, Chile (GRID:grid.412187.9); Facultad de Ciencias de la Vida, Universidad Andrés Bello, Santiago, Chile (GRID:grid.412848.3) (ISNI:0000 0001 2156 804X)
3 Centro de Estudios Avanzados de Enfermedades Crónicas (ACCDIS), Santiago, Chile (GRID:grid.412848.3); Instituto de Ciencias Biomédicas (ICBM), Facultad de Medicina, Universidad de Chile, Laboratorio de Comunicación Celular, Programa de Biología Celular y Molecular, Santiago, Chile (GRID:grid.443909.3) (ISNI:0000 0004 0385 4466)
4 Andes Biotechnologies/Fundación Ciencia & Vida, Santiago, Chile (GRID:grid.443909.3); Facultad de Ciencias de la Vida, Universidad Andrés Bello, Santiago, Chile (GRID:grid.412848.3) (ISNI:0000 0001 2156 804X)
5 Clínica Alemana-Universidad del Desarrollo, Centro de Medicina Regenerativa, Facultad de Medicina, Santiago, Chile (GRID:grid.412187.9) (ISNI:0000 0000 9631 4901); Andes Biotechnologies/Fundación Ciencia & Vida, Santiago, Chile (GRID:grid.412187.9)
6 University of Queensland Centre for Clinical Research, Royal Brisbane and Women’s Hospital, The University of Queensland, Exosome Biology Laboratory, Centre for Clinical Diagnostics, Brisbane, Australia (GRID:grid.412848.3)
7 Facultad de Medicina y Ciencia, Universidad San Sebastián, Cancer Cell Biology Lab., Centro de Biología Celular y Biomedicina (CEBICEM), Santiago, Chile (GRID:grid.442215.4)
8 Universidad de los Andes, Doctorado en Biomedicina, Centro de investigación e innovación Biomedica, Santiago, Chile (GRID:grid.440627.3) (ISNI:0000 0004 0487 6659)
9 Clínica Alemana-Universidad del Desarrollo, Centro de Medicina Regenerativa, Facultad de Medicina, Santiago, Chile (GRID:grid.412187.9) (ISNI:0000 0000 9631 4901)
10 Andes Biotechnologies/Fundación Ciencia & Vida, Santiago, Chile (GRID:grid.412848.3); Facultad de Ciencias de la Vida, Universidad Andrés Bello, Centro de Medicina Veterinaria, Santiago, Chile (GRID:grid.412848.3) (ISNI:0000 0001 2156 804X)